🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New Review - Temido et al - Overcoming the challenges of overtreating and undertreating inflammatory bowel disease thelancet.com/journals/langa… #GITwitter

The Lancet Oncology has joined Bluesky! 🦋Find and follow us at @thelancetoncol.bsky.social 🌐And, of course, online at thelancet.com/journals/lanon…

The Lancet Neurology has joined Bluesky! 🦋Find and follow us at bsky.app/profile/thelan… 🌐And, of course, online at thelancet.com/journals/laneu…

The Lancet Diabetes & Endocrinology has joined Bluesky! 🦋Find and follow us at bsky.app/profile/thelan… 🌐And, of course, online at thelancet.com/journals/landi…

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial hubs.li/Q035m-bZ0

Acute liver failure (ALF) is a life-threatening disorder. Although liver replacement is the best current therapy, artificial liver support systems may be beneficial to patients. A Seminar discusses the causes and management of ALF: hubs.li/Q035pgKj0

👋 Introducing The Lancet Primary Care, an OA journal dedicated to quality #primarycare for healthier societies. Find out more ➡️ bit.ly/412mFkR #medtwitter #familymedicine #internalmedicine

More Lancet on Bluesky 🙌 We’ve launched accounts for 17 Lancet journals, with more coming soon. Follow for the latest from our Editorial teams 👉 hubs.li/Q035yjKF0

Despite several therapeutic advances for inflammatory bowel disease (IBD), some patients are at risk of being undertreated or overtreated. In The Lancet Gastroenterology & Hepatology, a Review provides a practical guide aimed at avoiding undertreatment and overtreatment of IBD: hubs.li/Q035zCjX0

👇 Our letter on the sudden sabotage of disease control & #publichealth from the current #US administration. “The current catastrophic threat to #globalhealth must be stopped.” The Lancet Gastroenterology & Hepatology World Hepatitis Alliance Treatment Action Group (TAG) Kenneth Kabagambe Camilla Graham buff.ly/4hsVANG

New Correspondence - Wang et al - Pathogens don’t respect politicians: US federal disruption poses a new threat to global public health buff.ly/4hsVANG #MedTwitter #USAID #PEPFAR #NIH

NEW – final results from RESOLVE: Perioperative or postoperative #adjuvant #oxaliplatin with S1 vs adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma #gastriccancer #gicsm thelancet.com/journals/lanon…

The March issue of The Lancet Gastroenterology & Hepatology is out now at thelancet.com/gastrohep! Content includes: alcohol & cancer risk, colorectal cancer, inflammatory bowel disease, appendicitis, MASLD, viral hepatitis + more... #GITwitter #LiverTwitter #MedTwitter

I am so excited for our commentary published The Lancet Gastroenterology & Hepatology with colleagues Asgeir Johannessen Hepatitis B treatment in Africa: learning points from a scale-up programme in Ethiopia - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

🧵Just released! Our The Lancet Gastroenterology & Hepatology review explores the latest AUD management from a gastro/hepatology perspective 👉authors.elsevier.com/c/1kc078nByrCi…. ⬇️ Juan Pablo (JP) Arab, MD  Ramon Bataller Lorenzo Leggio MASLD Research Center UCSD Gastroenterology Facultad Medicina UC #LiverTwitter ALEH AASLD EASL Education

New Editorial - US policy changes put elimination of viral hepatitis at high risk thelancet.com/journals/langa… #LiverTwitter #IDTwitter #MedTwitter

SAIA is proud to have collaborated with researchers globally on groundbreaking new research in The Lancet Gastroenterology & Hepatology, called 'IBD in South Asia: A Scoping Review' sciencedirect.com/science/articl… #IBD is growing rapidly in #SouthAsia. This is the first publication to comprehensively review

Over 400 million people globally are affected by alcohol use disorder. In The Lancet Gastroenterology & Hepatology, a new Review explores the current management and treatment options for alcohol use disorder from a gastroenterology and hepatology-focused perspective: hubs.li/Q036ZgD40

1) Our study PET-HCC01 was recently published in Lancet Gastroenterology Hepatology testing the added value of 18F-fluorodeoxyglucose and 18F-fluorocholine PET-CT for staging optimization and treatment modification in hepatocellular carcinoma. The Lancet Gastroenterology & Hepatology EASL Education

🌍"IBD – A Global Disease Needs Global Solutions" 🎟️The Lancet G&H Commission invites🥼to participate in the Global IBD Preparedness Survey ⏳ 20 minutes | 🔐Confidential | 🌐 Multilingual 👉 Participate now bit.ly/3DgM9SP 📩 [email protected] 🔄 RETWEET